LPCN · Lipocine Inc. · Metrics
Market Cap
$12.04M
Shares
8.24M
Volume · Oct 28
194.59K
Avg daily vol (3M)
1.77M
LPCN metrics
76 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$1.51
Market cap
$12.04M
Price action
20 metricsPrice change (1W)
-9.9%
Price change (30D)
-30.1%
Price change (3M)
-31.8%
Price change (6M)
-36.8%
Price change (YTD)
-81.8%
Price change (1Y)
-48.2%
Trailing year
Price change (5Y)
—
52-week high
$11.26
52-week low
$1.44
Change from 52-week high
-87.0%
Change from 52-week low
+1.4%
Annualized volatility
110.1%
Annualized volatility (3M)
53.5%
Beta
1.6
RSI (14D)
29.2
Price vs SMA 50
-27.7%
Price vs SMA 200
-63.9%
Avg volume (3M)
1.77M
Relative volume
0.1
Average dollar volume
$3.84M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
8.24M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
4.4×
reciprocal yield 22.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
7.6×
reciprocal yield 13.1%
P / book
0.5
reciprocal yield 182.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-99.1%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
45.7×
reciprocal yield 2.2%
EV / revenue historical average (5Y)
45.7×
reciprocal yield 2.2%
EV / EBIT historical average (3Y)
23.6×
reciprocal yield 4.2%
EV / EBIT historical average (5Y)
23.6×
reciprocal yield 4.2%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
-800.8%
Trailing 12 months
Net margin
-755.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$12.57M
Net income (TTM)
−$11.85M
Trailing 12 months
Diluted EPS (TTM)
$-1.79
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-69.5%
Year over year
Net income growth YoY
-115,371.9%
Revenue (TTM)
$1.57M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+53.5%
Year over year · more shares
Revenue CAGR (3Y)
+58.1%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-54.4%
Return on assets
-49.7%
Debt / equity
0.0
Current ratio
11.5
EBITDA (TTM)
−$12.51M
Free cash flow (TTM)
—
Quick ratio
11.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$4.98M
Latest balance sheet
Cash & equivalents
$4.98M
Total assets
$23.84M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$11.19M
Capital expenditures (TTM)
$13,167
R&D (TTM)
$10.19M
SG&A (TTM)
—
Stock compensation (TTM)
$229,833
R&D / revenue
649.4%
Stock compensation / revenue
14.6%
Ownership (13F)
9 metrics13F filers
36
13F filer change QoQ
-11
Institutional ownership
36.2%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
27.4%
Private-fund adviser ownership
25.9%
Active holders' share change QoQ
-7.6%
Holder tenure
4.1
Price vs estimated holder cost
-57.5%
Ownership (registered funds)
1 metricsIndex-fund ownership
3.1%
Short interest
3 metricsShort interest
4.3%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
51 / 100
Insider activity
2 metricsNet insider buying (90D)
$82,174
Insider-sentiment score
83 / 100
Risk flags
1 metricsGoing concern
—